A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis

New England Journal of Medicine

Volumn 334, Issue 6, 1996, Pages 341-348

  Greco, Donato ^a   Salmaso, Stefania ^a   Mastrantonio, Paola ^a   Giuliano, Marina ^a   Tozzi, Alberto E ^a   Anemona, Alessandra ^a   Ciofi Degli Atti, Marta L ^a   Giammanco, Anna ^b   Panei, Pietro ^a   Blackwelder, Willlam C ^c   Klein, David L ^c   Wassilak, Steven G F ^c   Stefanelli, P ^d   Bottone, M ^d   Sofia, T ^d   Luzi, S ^e   Bellomi, G ^e   Cobianchi, F ^e   Canganella, G ^e   Meduri, F ^e   Scuderi, G ^a   Chiarini, A ^b   Maggio, M ^b   Taormina, S ^b   Genovese, M ^b   Moiraghi, A ^b   Barale, A ^b   Di Tommaso, S ^b   Malaspina, S ^b   Vasile, E ^b   Ferraro, P ^b   Dal Lago, P ^b   De Marzi, L ^b   Robino, L ^b   Giraldo, E ^b   Coppola, N ^b   Materassi, P ^b   Castellani, Tarabini ^b   Basso, F ^b   Barbuti, S ^b   Quarto, M ^b   Lopalco, P ^b   D'Orazio P ^b   Sanguedolce, A ^b   more..

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d Laboratory of Bacteriology and Medical Mycology

^e Laboratory of Epidemiology and Biostatistics

Author keywords

[No Author keywords available]

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; DIPHTHERIA TETANUS TOXOID; HEMAGGLUTININ; PERTUSSIS TOXIN;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYANOSIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEVER; HUMAN; IMMUNOGENICITY; INFANT; INJECTION PAIN; INTRAMUSCULAR DRUG ADMINISTRATION; IRRITABILITY; ITALY; MAJOR CLINICAL STUDY; MUSCLE HYPOTONIA; PERTUSSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEIZURE; VACCINATION;

EID: 13344286322     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199602083340601     Document Type: Article

References (39)

1. Kanai K. Japan's experience in pertussis epidemiology and vaccination in the past thirty years Jpn J Med Sci Biol 1980,33 107-43.
2. Miller DL, Alderslade R, Ross EM. Whooping cough and whooping cough vaccine, the risks and benefits debate. Epidemiol Rev 1982;4:1-24.
3. Romanus V, Jonsell R, Bergquist S-O. Pertussis in Sweden after the cessation of general immunization in 1979 Pediatr Infect Dis J 1987;6:364-71.
4. Howson CP, Howe CJ, Fineberg HV. Adverse effects of pertussis and rubella vaccines: a report of the Committee to Review the Adverse Consequences of Pertussis and Rubella Vaccines. Washington, D.C.: National Academy Press, 1991.
5. Kimura M, Kuno-Sakai H. Current epidemiology of pertussis in Japan. Pediatr Infect Dis J 1990;9:705-9.
6. Mortimer EA Jr, Kimura M, Cherry JD, et al Protective efficacy of the Takeda acellular pertussis vaccine combined with diphtheria and tetanus toxoids following household exposure of Japanese children. Am J Dis Child 1990;144:899-904.
7. Ad Hoc Group for the Study of Pertussis Vaccines Placebo-controlled trial of two acellular pertussis vaccines in Sweden - protective efficacy and adverse events Lancet 1988;1:955-60. [Erratum, Lancet 1988,1:1238.]
8. The Italian Vaccine Coverage Survey Working Group. Childhood vaccination coverage in Italy, results of a seven-region survey. Bull World Health Organ 1994;72:885-95.
9. Binkin NJ, Salmaso S, Tozzi AE, Scuderi G, Greco D. Epidemiology of pertussis in a developed country with low vaccination coverage: the Italian experience. Pediatr Infect Dis J 1992;11:653-61
10. Oda M, Cowell JL, Burstyn DG, Manclark CR. Protective activities of the filamentous hemagglutinin and the lymphocytosis-promoting factor of Bordetella pertussis in mice. J Infect Dis 1984;150:823-33.
11. Shahin RD, Brennan MJ, Li ZM, Meade BD, Manclark CR. Characterization of the protective capacity and immunogenicity of the 69-kD outer membrane protein of Bordetella pertussis. J Exp Med 1990;171:63-73.
12. Pizza M, Covacci A, Bartoloni A, et al. Mutants of pertussis toxin suitable for vaccine development. Science 1989;246.497-500.
13. Blackwelder WC. Sample size and power for prospective analysis of relative risk. Stat Med 1993;12:691-8.
14. Manclark CR, Meade BD, Burstyn DG Serological response to Bordetella pertussis. In. Rose NR, Friedman H, Fahey JL, eds. Manual of clinical laboratory immunology. 3rd ed. Washington, D.C.: American Society for Microbiology, 1986:388-94.
15. Gillenius P, Jäätmaa E, Askelöf P, Granstrom M, Tiru M. The standardization of an assay for pertussis toxin and antitoxin in microplate culture of Chinese hamster ovary cells J Biol Stand 1985;13:61-6.
16. Miyamura K, Tajiri E, Ito A, Murata R, Kono R. Micro cell culture method for determination of diphtheria toxin and antitoxin titres using VERO cells. II Comparison with the rabbit skin method and practical application for seroepidemiological studies. J Biol Stand 1974,2:203-9.
17. Pitzurra M, Bistoni F, Pitzurra L, Marconi B. Use of turkey red blood cells in the passive haemagglutination test for studying tetanus immunity. Bull World Health Organ 1983;61:331-8.
18. van der Zee A, Agterberg C, van Agterveld M, Peeters M, Mooi FR. Characterization of IS1001, an insertion sequence element of Bordetella parapertussis. J Bacteriol 1993;175:141-7.
19. van der Zee A, Agterberg C, Peeters M, Schellekens J, Mooi FR. Polymerase chain reaction assay for pertussis: simultaneous detection and discrimination of Bordetella pertussis and Bordetella parapertussis. J Clin Microbiol 1993;31:2134-40.
20. Breslow NE, Day NE. Statistical methods in cancer research. Vol. 2. The design and analysis of cohort studies. Lyon, France: International Agency for Research on Cancer, 1987. (IARC scientific publications no 82.)
21. Clopper CJ, Pearson ES. The use of confidence or fiducial limits illustrated in the case of the binomial Biometrika 1934;26:404-13
22. Johnson NL, Kotz S. Discrete distributions Boston: Houghton Mifflin, 1969.
23. Kleinbaum DG, Kupper LL, Morgenstern H. Epidemiologic research: principles and quantitative methods. Belmont, Calif.: Lifetime Learning, 1982.
24. Gustafsson L, Hallander HO, Olin P, Reizenstein E, Storsaeter J. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N Engl J Med 1996;334 349-55
25. Trollfors B, Taranger J, Lagergård T, et al. A placebo-controlled trial of a pertussis-toxoid vaccine. N Engl J Med 1995;333:1045-50.
26. Schmitt H-J, Wirsing von Konig C-H, Neiss A, et al Efficacy of acellular pertussis vaccine in early childhood after household exposure. JAMA 1996,275. 37-41.
27. Edwards KM. Acellular pertussis vaccines - a solution to the pertussis problem? J Infect Dis 1993,168:15-20.
28. Liese JG, Harzer E, Meschievitz CK, et al. Case-control study to evaluate the efficacy of BIKEN acellular pertussis vaccine (Tripedia) combined with diphtheria and tetanus toxoids (DTacP) in infants In. Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, September 17-20, 1995. Washington, D.C.. American Society for Microbiology, 1995.173. abstract.
29. Hallander HO, Storsaeter J, Möllby R. Evaluation of serology and nasopharyngeal cultures for diagnosis of pertussis in a vaccine efficacy trial. J Infect Dis 1991;163:1046-54.
30. Edwards KM, Meade BD, Decker MD, et al. Comparison of 13 acellular pertussis vaccines: overview and serologic response. Pediatrics 1995,96.548-57.
31. Edwards KM, Decker MD, Halsey NA, et al. Differences in antibody response to whole-cell pertussis vaccines. Pediatrics 1991;88 1019-23.
32. Kaplan SL, Lauer BA, Ward MA, et al. Immunogenicity and safety of Haemophilus influenzae type b-tetanus protein conjugate vaccine alone or mixed with diphtheria-tetanus-pertussis vaccine in infants. J Pediatr 1994;124:323-7.
33. Halperin SA, Bortolussi R, MacLean D, Chisholm N. Persistence of pertussis in an immunized population, results of the Nova Scotia Enhanced Pertussis Surveillance Program. J Pediatr 1989,115:686-93.
34. Baker JD, Halperin SA, Edwards K, Miller B, Decker M, Stephens D. Antibody response to Bordetella pertussis antigens after immunization with American and Canadian whole-cell vaccines. J Pediatr 1992;121:523-7
35. Fine PEM, Clarkson JA. Reflections on the efficacy of pertussis vaccines Rev Infect Dis 1987,9.866-83.
36. Onorato IM, Wassilak SG, Meade B Efficacy of whole-cell pertussis vaccine in preschool children in the United States. JAMA 1992;267:2745-9.
37. Blennow M, Granström M, Jäätmaa E, Olin P. Primary immunization of infants with an acellular pertussis vaccine in a double-blind randomized clinical trial. Pediatrics 1988;82:293-9.
38. Cody CL, Baraff LJ, Cherry JD, Marcy SM, Manclark CR. Nature and rates of adverse reactions associated with DTP and DT immunizations in infants and children. Pediatrics 1981;68:650-50.
39. Decker MD, Edwards KM, Steinhoff MC, et al Comparison of 13 acellular pertussis vaccines: adverse reactions. Pediatrics 1995;96:557-66.